Bruker(US:BRKR)2025-08-04 12:30Q2 2025 Financial Performance - Revenue decreased by $3.3 million, a -0.4% decline[7] - Organic revenue declined by -7.0%, with BSI down -7.2% and BEST down -4.8%[7] - Non-GAAP EPS was $0.32, a decrease of -38.5%, including a $0.06 FX headwind[7, 39] - Non-GAAP operating margin decreased to 9.0%, down -480 bps[7] H1 2025 Financial Performance - Revenue increased by $76.4 million, a 5.0% increase[9] - Organic revenue declined by -2.3%, with BSI down -1.4% and BEST down -11.5%[9] - Acquisition contributed +6.5% to revenue[9] - Non-GAAP EPS was $0.78, a decrease of -25.7%, including a $0.08 FX headwind[9, 42] - Non-GAAP operating margin decreased to 10.9%, down -300 bps[9] FY 2025 Outlook - Revenue is projected to be between $3.43 billion and $3.50 billion, representing a growth of +2% to +4%[48] - Organic revenue is expected to decline by -2% to -4%[48] - M&A is expected to contribute approximately +3.5% to revenue[48] - Non-GAAP EPS is projected to be between $1.95 and $2.05, a decline of -15% to -19%[48]